Please assess the completion status of the following clinical trial:

Trial Title: PTNS vs Botox of Refractory OAB

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: COHORT
- Primary Purpose: None
- Time Perspective: PROSPECTIVE
- Masking: None
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~1. Women with refractory OAB (dry or wet)~2. OAB will be defined by a positive response and bother of somewhat, quite a bit, a great deal, or a very great deal to question #3 or #8 on the OAB-q (see appendix B) regarding urinary urgency and urgency incontinence.~3. Refractory will be defined as failure of 2 prior treatments, including behavioral modification, pelvic floor physical therapy, and OAB medication (anticholinergics or mirabegron). Trial of 2 medications that did not improve symptoms after 2 weeks or could not be tolerated due to side effects will constitute 2 treatment failures.~4. Women with mixed urinary incontinence that is urge predominant will also be included.~5. Age ≥ 18 years~6. English speaking~7. Available for 1 year follow-up~8. Able to complete study questionnaires~Exclusion Criteria:~1. Neurologic disease known to cause OAB including, but not limited to, Multiple sclerosis, Parkinson's disease, and Spinal Cord Injury.~2. Pregnancy by self-report or pregnancy test~3. Contraindication to PTNS and/or BTX~   * PTNS: Pacemaker~  * BTX: myasthenia gravis, allergy to BTX, urinary retention (post void residual \>200cc)~4. Planned surgery for pelvic floor disorder during the study period~5. Prior treatment with BTX, PTNS, or sacral nerve stimulation (SNS) for refractory OAB/urinary urge incontinence (UUI)

- Gender: FEMALE
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- OnabotulinumtoxinA (BoNTA) (Type: None): DRUG: OnabotulinumtoxinA (BoNTA) is an injection into the bladder which blocks the presynaptic release of acetylcholine. BoNTA was approved for the treatment of OAB by the FDA in 2013.
- Percutaneous tibial nerve stimulation (PTNS) (Type: None): DEVICE: PTNS involves needle stimulation of the posterior tibial nerve and is typically performed with weekly 30 minute sessions for a 12 week treatment course.

Based on this trial design, predict the completion outcome and termination type (if applicable).